Email updates

Keep up to date with the latest news and content from Experimental Hematology and Oncology and BioMed Central.

Open Access Research

Clinical significance of E2F1 protein expression in non-small cell lung cancer

Jung-Jyh Hung12, Chung-Tsen Hsueh3, Kuan-Hua Chen4, Wen-Hu Hsu12 and Yu-Chung Wu12*

Author Affiliations

1 Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, 112, Taiwan

2 School of Medicine, National Yang-Ming University, Taipei, 112, Taiwan

3 Division of Medical Oncology and Hematology, Loma Linda University, Loma Linda, California, USA

4 Department of Health Risk Management, School of Public Health, China Medical University, Taichung, Taiwan

For all author emails, please log on.

Experimental Hematology & Oncology 2012, 1:18  doi:10.1186/2162-3619-1-18

Published: 20 July 2012

Abstract

Background

The transcription factor E2F1 has been implicated in cell cycle control and DNA damage response. Paradoxically, E2F1 can promote apoptosis and function as tumor suppressor. In non-small cell lung cancer (NSCLC), there are conflicting data for clinical significance of E2F1 expression. In this study, we investigated the protein expression of E2F1 in patients with stage I-III NSCLC, and its correlation with clinical outcome.

Results

56 paired adjacent non-tumor/tumor matched samples were prospectively obtained from patients undergoing surgery for stage I-III NSCLC at Taipei Veterans General Hospital. The protein expression of E2F1 was determined by Western blot analysis. The levels of E2F1 protein were significantly higher in tumor samples than in non-tumor lung specimens (P = 0.008). Overexpression of E2F1 was defined as a more than 2-fold expression in the tumorous sample compared with the corresponding nontumorous one, and was noted in 21 patients (37.5%). There was no significant difference in overall survival (P = 0.44) or probability of freedom from recurrence (P = 0.378) between patients with E2F1 overexpression vs. non-overexpressors. Additionally, there was no significant association between E2F1 overexpression and any clinicopathologic parameter such as histological type, stage, or angiolymphatic invasion of tumor.

Conclusion

E2F1 protein is frequently overexpressed in NSCLC. There is no correlation between E2F1 protein expression and clinical outcome such as survival and freedom from progression.

Keywords:
E2F1; Protein expression; Non-small cell lung cancer; Survival; Freedom from recurrence